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Abstract:  
Data Sources:  
Cochrane Cystic Fibrosis and Genetic Disorders Group’s Coagulopathies Trials 
Register, a regularly updated database informed by trials identified within electronic 
databases including MEDLINE. Further defined searches were undertaken in 
PubMed, Embase, The Cochrane Library, ClinicalTrials.gov and WHO International 
Clinical Trials Registry Platform. Additional hand searching of relevant journals and 
books of conference proceedings was undertaken. 
 
Study selection:   
Randomised and quasi-randomised controlled trials in people of all ages with 
haemophilia or VWD undergoing oral or dental procedures using antiﬁbrinolytic 
agents (tranexamic acid (TXA) or epsilon aminocaproic acid (EACA)) to prevent 
perioperative bleeding compared to no intervention with or without placebo. 
 
Data extraction and synthesis: 
Two authors independently assessed identified publications for inclusion based on 
defined selection criteria. The two authors performed data extraction and risk of bias 
assessments using standardised forms and the Cochrane risk of bias tools. A third 
author, deemed to have particular subject expertise, verified eligibility of inclusion.   
 
Results:  
One randomised, double-blinded placebo controlled trial and one quasi randomised 
trial were included. A total of 59 participants with haemophilia undergoing dental 
extraction were involved.  Both trials evidenced a notable reduction in post-operative 
bleeding following dental extraction when either TXA or EACA were used, in addition 
to routine preoperative factor replacement, when compared to placebo. The number 
of post-operative bleeds, amount of blood loss and the need for additional clotting 
factors were reduced in the groups receiving antifibrinolytic therapy. No eligible trials 
in people with VWD were identified. 
 
Conclusions: 
 
Low quality evidence exists to support the use of adjuvant antifibrinolytic therapy to 
reduce perioperative bleeding in patients with haemophilia undergoing dental 
extraction.  The limited number of trials identified (N=2), minimal sample size (N=28, 
N=31),) and historic nature of the studies, originating from the 1970’s, in addition to 
study heterogeneity and subsequent selection bias results in a low quality evidence 
grade for recommended adjuvant antifibrinolytic therapy. There is no clear indication 
to alter current practice utilising antifibrinolytic therapy to manage patients with 
haemophilia undergoing dental surgery in accordance with internationally accepted 
guidelines. However, further research with standardised study deigns would be 
welcomed in order enhance the evidence base in the management in people with 
haemophilia and VWD.  
  
Commentary: 
Haemophilia A (deficiency in factor VIII), B (deficiency in factor IX) and Von 
Willibrand Disease (VWD) are all inherited bleeding disorders. Congenital disorders 
of the coagulation system increase the risk of significant bleeding complications 
during or after dental extraction or minor oral surgery (1).  Affected individuals 
typically bleed for longer periods of time and may experience prolonged bleeding 
due to clot instability but do not bleed more profusely than people with normal 
coagulation. Historically, the oral health management of people with Haemophilia 
was exclusively provided within the secondary care environment.  A gradual shift 
towards the sharing of care between primary and secondary services now exists 
(1,2).   
 
Safe and successful patient centred management for people with inherited bleeding 
disorders requires collaborative multi-disciplinary working between haematology and 
dental teams.  The severity of the bleeding disorder will influence the level of medical 
intervention necessary to ensure the safe delivery of dental care. Defective 
coagulation may require the utilisation of factor concentrate or desmopressin in 
addition to local haemostatic techniques and the appropriate use of antifibrinolytic 
agents to prevent catastrophic bleeds following haemostatic challenge including 
dental intervention.   
The use of factor replacement therapy is associated with risks including the 
transmission of blood borne viruses and the development of inhibitors or antibodies 
(3). The latter risk negates further use of factor replacement as a consequence of 
immune mediated response.  It is desirable to minimise the use of replacement 
factor from both a risk and cost perspective. Thus strategies to prevent dental 
disease and reduce the risk of operative intervention in those with inherited bleeding 
disorders is essential.  
 
The authors were specific in the setting of their review selection criteria, including 
only studies which were both randomised and controlled.  Thus very few trials were 
included (N=2) limiting the authors in their ability to perform planned sensitivity 
analysis and draw high powered conclusions.  A methodological approach to the 
literature search resulted in a wide range of databases being explored.  However, 
only studies written in English, Dutch, French or German were included. This has 
limited the authors in the expanse of their literature search. The authors adopted 
review methodology resulted in no studies involving people with WVD being eligible 
for inclusion.  Thus a key part of the study question posed remains unanswered. 
 
The Haemophilia studies included in the review (5, 6) display significant 
heterogeneity across sample size and intervention methodologies. In both studies all 
participants received factor replacement prior to dental extraction, therefore it can be 
assumed that antifibrinolytic therapy is not a replacement for appropriate levels of 
factor to facilitate haemostasis. Due to small sample sizes, participants with mild, 
moderate and severe disease were combined into a single group for analysis in both 
studies. The lack of discrimination between severity of disease and outcome with 
intervention hinders the clinical implications of the research presented. 
Furthermore, the studies varied in the antifibrinolytic agent used, the dosing and 
frequency of agent used, whilst in one study dental extractions where performed 
under general anaesthetic and in the other with the use of local anaesthetic. 
Furthermore, the additional use of an acrylic plate to protect the formed clot may 
have masked the true effect of the EACA.  Additionally, the authors of the review 
highlighted the potential risk of bias in this study.  
Such discord between study design inhibits the ability to truly compare data and 
subsequently inform evidence based practice.  
 
The quality of evidence which currently exists to inform the recommended use of 
adjuvant antifibrinolytic therapy in the management of patients with inherited 
bleeding disorders undergoing dental extraction is poor. However, despite the 
limitations there does appear to be benefit in the use of adjuvant therapy to reduce 
perioperative bleeding with no significant side effects of the therapy encountered. At 
present, clinicians should conform to existing guidelines which recommend the use 
of adjuvant antifibrinolytic therapy (6). However, the research and clinical community 
involved in the care of people with inherited bleeding disorders are encouraged to 
seek higher quality evidence from which to inform management strategies.  
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